Inicio>>Signaling Pathways>> PROTAC>> PROTAC>>ZXH-4-130 TFA

ZXH-4-130 TFA

Catalog No.GC64135

ZXH-4-130 TFA es un degradador altamente potente y selectivo de CRBN.

Products are for research use only. Not for human use. We do not sell to patients.

ZXH-4-130 TFA Chemical Structure

Cas No.: 2711006-67-4

Tamaño Precio Disponibilidad Cantidad
5 mg
432,00 $
Disponible
10 mg
720,00 $
Disponible
25 mg
1.485,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ZXH-4-130 TFA is a highly potent and selective degrader of CRBN. ZXH-4-130 is a CRBN-VHL compound (hetero-PROTAC). ZXH-4-130 TFA induces ~80% CRBN degradation at 10 nM in MM1.S cells[1].

ZXH-4-130 (100 nM; 2 h pre-treatment; followed by 96-hour treatment with 1 μM of Pomalidomide) TFA prevents Pomalidomide (1 μM) cytotoxicity to a significant extent, ZXH-4-130 TFA has statistically significant amounts of prevention[1].ZXH-4-130 TFA (pretreatment with 50 nM) rescues GSPT1 degradation induced by CC-885 in MM1.S cells[1].ZXH-4-130 (100 nM; 2 h pre-treatment; followed by 6 h treatment with THAL-SNS-032)TFA induces nearly complete CRBN degradation, but THAL-SNS-032’s activity against CDK9 is only partially prevented[1].

[1]. Chelsea E Powell, et al. Selective degradation-inducing probes for studying cereblon (CRBN) biology. RSC Med Chem. 2021 Jul 6;12(8):1381-1390.

Reseñas

Review for ZXH-4-130 TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ZXH-4-130 TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.